A Review of the Vitiligo Literature to Standardize Expression of Disease Severity.

IF 1.5 4区医学 Q3 DERMATOLOGY Journal of Drugs in Dermatology Pub Date : 2024-10-01 DOI:10.36849/JDD.2024.8049

Yael Renert-Yuval, Seemal Desai, Victor Huang, Samantha Walsh, David Rosmarin, Nanette Silverberg

{"title":"A Review of the Vitiligo Literature to Standardize Expression of Disease Severity.","authors":"Yael Renert-Yuval, Seemal Desai, Victor Huang, Samantha Walsh, David Rosmarin, Nanette Silverberg","doi":"10.36849/JDD.2024.8049","DOIUrl":null,"url":null,"abstract":"Background: The literature on vitiligo is heterogeneous with limited standardization in vitiligo disease severity reporting.Objectives: The IDEOM Vitiligo Workgroup initiated a project to develop an improved understanding of clinical reporting of vitiligo severity.Methods: A medical librarian-developed literature review identified 50 clinical trials treating vitiligo topically using topical corticosteroids or topical tacrolimus that included adult and pediatric patients, with 10 or more patients, with grading by SORT criteria.Results: Grading systems used included body surface area scoring (BSA) clinically or via photography and mapping. Most studies create a grading system of repigmentation including G0- no change, G1- 1-25%, G2- 26-50%, G3- 51-75%, G4- 75-99%, and G5- 100%. Variations include reporting success as thresholds >25% (G2-G5), >50% (G3-G5), and >75% (G4-G5) repigmentation. Vitiligo Area Scoring Index (VASI), Dermatology Life Quality Index (DLQI), patient satisfaction, and the vitiligo noticeability scale are all standardized scoring systems that have been used in clinical studies. Other metrics reported include onset and maintenance of response, treatment burden, side effects, and cost-effectiveness.Conclusions: BSA total and quartiles of improvement are the most commonly reported metrics in studies with high-level evidence. The addition of categories of no improvement, complete clearance, spontaneous improvement, and worsening appears to enhance information collection. Collection of data using photographs or computer-assisted BSA monitoring enhances data reproducibility. Thresholds of success should include 25%, 50%, 75%, and adding 90% and 100% repigmentation. VASI represents a validated collection method, which can be modified for 50%, 75%, and 90% improvement. Newer metrics including treatment burden and cost effectiveness are emerging metrics under evaluation. J Drugs Dermatol. 2024;23(10):842-846. doi:10.36849/JDD.8049.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"23 10","pages":"842-846"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.2024.8049","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The literature on vitiligo is heterogeneous with limited standardization in vitiligo disease severity reporting.

Objectives: The IDEOM Vitiligo Workgroup initiated a project to develop an improved understanding of clinical reporting of vitiligo severity.

Methods: A medical librarian-developed literature review identified 50 clinical trials treating vitiligo topically using topical corticosteroids or topical tacrolimus that included adult and pediatric patients, with 10 or more patients, with grading by SORT criteria.

Results: Grading systems used included body surface area scoring (BSA) clinically or via photography and mapping. Most studies create a grading system of repigmentation including G0- no change, G1- 1-25%, G2- 26-50%, G3- 51-75%, G4- 75-99%, and G5- 100%. Variations include reporting success as thresholds >25% (G2-G5), >50% (G3-G5), and >75% (G4-G5) repigmentation. Vitiligo Area Scoring Index (VASI), Dermatology Life Quality Index (DLQI), patient satisfaction, and the vitiligo noticeability scale are all standardized scoring systems that have been used in clinical studies. Other metrics reported include onset and maintenance of response, treatment burden, side effects, and cost-effectiveness.

Conclusions: BSA total and quartiles of improvement are the most commonly reported metrics in studies with high-level evidence. The addition of categories of no improvement, complete clearance, spontaneous improvement, and worsening appears to enhance information collection. Collection of data using photographs or computer-assisted BSA monitoring enhances data reproducibility. Thresholds of success should include 25%, 50%, 75%, and adding 90% and 100% repigmentation. VASI represents a validated collection method, which can be modified for 50%, 75%, and 90% improvement. Newer metrics including treatment burden and cost effectiveness are emerging metrics under evaluation. J Drugs Dermatol. 2024;23(10):842-846. doi:10.36849/JDD.8049.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

回顾白癜风文献，统一疾病严重程度的表达方式。

背景：有关白癜风的文献种类繁多，白癜风疾病严重程度报告的标准化程度有限：IDEOM 白癜风工作组发起了一个项目，旨在加深对白癜风严重程度临床报告的理解：方法：医学图书管理员编写了一份文献综述，确定了50项使用皮质类固醇激素或他克莫司外用治疗白癜风的临床试验，这些试验包括成人和儿童患者，患者人数在10人或10人以上，并按照SORT标准进行了分级：使用的分级系统包括临床体表面积评分（BSA）或摄影和绘图。大多数研究建立了再色素沉着分级系统，包括 G0- 无变化、G1- 1-25%、G2- 26-50%、G3- 51-75%、G4- 75-99% 和 G5-100%。不同的方法包括以 25%（G2-G5）、50%（G3-G5）和 75%（G4-G5）的色素再形成阈值来报告成功率。白癜风面积评分指数（VASI）、皮肤科生活质量指数（DLQI）、患者满意度和白癜风可察觉性量表都是临床研究中使用的标准化评分系统。报告的其他指标包括反应的开始和维持、治疗负担、副作用和成本效益：结论：BSA 总分和四分位数的改善是高水平证据研究中最常报告的指标。增加无改善、完全清除、自发改善和恶化等类别似乎能加强信息收集。使用照片或计算机辅助 BSA 监测收集数据可提高数据的可重复性。成功的阈值应包括 25%、50%、75%，并增加 90% 和 100% 的色素再沉着。VASI 是一种经过验证的收集方法，可根据 50%、75% 和 90% 的改善情况进行修改。包括治疗负担和成本效益在内的新指标是正在评估的新兴指标。J Drugs Dermatol.2024;23(10):842-846. doi:10.36849/JDD.8049.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Drugs in Dermatology DERMATOLOGY-

CiteScore

2.20

自引率

13.30%

发文量

289

审稿时长

3-6 weeks

期刊介绍： The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.